Image-guided therapy
Lead management devices and extraction
Lead with clarity. Manage with confidence.
Cardiac implantable electronic device (CIED) patients are at the core of what you do. Our lead management devices allow safe and effective extraction of CIED leads, providing improved outcomes for patients.
Demonstrated results in lead management devices and extraction
Lead extraction is life-saving, yet patients are undertreated
New data in JAMA Cardiology found that >8 in 10 patients with CIED infection are not treated according to Class 1 guidelines. Yet, lead extraction within 6 days of diagnosis is associated with a 42.8% lower risk of death [8]. Philips is dedicated to helping you recognize and treat implanted cardiac device infections by providing expert tools, training and support that help you save lives and vastly improve the quality of life for your patients.
Benefits
- With early diagnosis and appropriate treatment, cardiac device infections can be cured [8].
- Lead extraction is proven to be safe [6,9] and all major cardiac society guidelines recommend complete system removal of hardware and leads when an infection is present [10,11].
- Lead extraction has a 97.7% clinical success rate [6].
Improved patient outcomes with Philips lead management portfolio of safe and effective tools
- A multi-year study showed proper Bridge Plus utilization increased SVC tear survival from 56.4% to 88.2% [7].
- Lead extraction has a 99.72% procedural safety rate [6].
Featured solutions for lead management devices and extraction
HRS Releases 2026 Expert Consensus Update for CIED Lead Management
The 2026 HRS consensus statement provides updated clinical guidelines for cardiac implantable electronic device (CIED) lead management and extraction. Emphasizing patient safety and best practices, these recommendations help clinicians identify candidates, minimize procedural risks, and improve outcomes in CIED lead extraction.
GlideLight Laser Sheath
Effectively removing leads depends on tools that provide safety, control, and efficiency. When a laser is used for lead extraction, over 99.5% of patients are free from SVC-related complications [12]. GlideLight Laser Sheath only ablates where the sheath touches tissue [13] and provides a high degree of control during lead extraction, with efficient advancement to ease lead extraction [14,15].
Bridge Plus Occlusion Balloon
A tear in the superior vena cava (SVC) during a lead extraction procedure is rare, occurring in less than 0.5% of cases [16]. But when a tear does occur, every second counts. Bridge Plus Occlusion Balloon deploys in less than 2 minutes [17], stops up to 90% of blood loss [18] and maintains acceptable hemostasis for at least 30 minutes [19], giving you time to stabilize your patient and transition to surgery.
By removing the pacemaker, I’ve been able to get on with my life and be more optimistic about tomorrow, and I can live again.
Jerry
Patient
Footnotes
- Pokorney et al. Outcomes Associated with Extraction versus Capping and Abandoning Pacing and Defibrillator Leads. Circulation 2017 Oct 10;136(15):1387–1395.
- Mattei E et al. Impact of capped and uncapped abandoned leads on the heating of an MR-conditional pacemaker implant. Magn Reson Med 2015;73:390–400.
- Oginosawa Y et al. The incidence and risk factors for venous obstruction after implantation of transvenous pacing leads. Pacing Clin Electrophysiol 2002;25:1605–1611.
- Kutarski A et al. Pacemaker lead extraction and recapture of venous access: technical problems arising from extensive venous obstruction. Cardiology Journal 2012;19(5):513–517.
- Sohail M et al. Laser lead extraction to facilitate cardiac implantable electronic device upgrade and revision in the presence of central venous obstruction. Europace 2014;16(1):81–87.
- Wazni O et al. Lead extraction in the contemporary setting: the LExICon study: A Multicenter Observational Retrospective Study of Consecutive Laser Lead Extractions. J Am Coll Cardiol. 2010;55(6):579–586.
- Azarrafiy R et al. The Endovascular Occlusion Balloon for Treatment of Superior Vena Cava Tears During Transvenous Lead Extraction: A Multi-Year Analysis and An Update to Best Practice Protocol. Circulation: Arrhythmia and Electrophysiology, August 2019.
- Pokorney SD et al. Lead Extraction and Mortality Among Patients With Cardiac Implanted Electronic Device Infection. JAMA Cardiol. Published online October 18, 2023. doi:10.1001/jamacardio.2023.3379.
- Bongiorni MG et al. The European Lead Extraction ConTRolled (ELECTRa) study. Eur Heart J. 2017;38(40):2995–3005.
- Cha, et al. 2026 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction. Heart Rhythm, April 2026.
- Blomström-Lundqvist C et al. EHRA international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections. Europace (2020) 22, 515–516 and European Heart Journal (2020) 41, 2012–2032.
- Rinaldi CA et al. Safety and success of transvenous lead extraction using excimer laser sheaths: a meta-analysis of over 1700 patients. EP Europace, Volume 25, Issue 11, November 2023.
- Mechanism and Implementation of Catheter-Based Ultraviolet Photoablation. Philips Data on File, Document ref: 7030-0619.
- Reduced advancement force lowers the forces applied to leads during extraction. D015861-01, Data on file at Philips.
- A bench top study comparison (Test method D011154) of average peak push forces required to advance Laser Sheath at 40Hz vs. 80Hz (GlideLight compared to SLS II) by use of the data collected in D015786, as well as the Design Verification report D015722. Data on file at Philips.
- Azarrafiy, Ryan et al. “Endovascular Occlusion Balloon for Treatment of Superior Vena Cava Tears During Transvenous Lead Extraction: A Multiyear Analysis and an Update to Best Practice Protocol.” Circulation. Arrhythmia and electrophysiology vol. 12,8 (2019):
- Document on file D002023609_A. Bridge M&M Marketing Claims Test Report. Average timed deployment for commercial Bridge was 74.33 seconds and Bridge Plus was 58.33 seconds.
- Document on File, D027561 Marketing claims blood loss report for Bridge project 1338 - When deployed, the Bridge Occlusion Balloon reduces blood loss of an SVC tear by 89.7% (α=0.10), on average, in an animal model.
- Document on file, D026197 & animal study - NGX028-IS17 - All animals had biological metrics measured for up to 45 minutes during occlusion and 15 minutes post device deployment.
Disclaimer
GlideLight Laser Sheath important safety information
The GlideLight Laser Sheath is intended for use with other lead extraction tools in patients who are suitable candidates for removal of implanted pacemaker and defibrillator leads. The use of the GlideLight Laser Sheath may be unsafe in some patients, or with certain leads, or when the leads cannot be extracted through the superior veins (that is, when groin or surgical extraction is required). Rarely a patient undergoing lead extraction may require urgent surgical treatment for a complication; therefore, patients should not undergo lead extraction with a laser sheath in centers where emergency surgical procedures cannot be performed. Leads not intended for extraction may be damaged during the procedure and may require replacement.
Potential minor adverse events associated with lead extraction procedures that may or may not require medical or surgical treatment include: a tear or damage to the blood vessels, the heart or its structures; bleeding at the surgical site; or collapsed lung.
Rare but serious adverse events that require emergency medical or surgical procedures may include: a tear or damage to the blood vessels, the heart, lungs or their structures; blood clot or obstruction of the blood vessels or lungs by debris or lead fragments. Other serious complications may include irregular heartbeat, weakened heart muscle, infection, respiratory failure, or complications associated with anesthesia, stroke, or death.
This information is not intended to replace a discussion with your healthcare provider on the benefits and risks of this procedure to you.
TightRail, TightRail Mini, TightRail Sub-C important safety information The TightRail, TightRail Mini, and TightRail Sub-C Rotating Dilator Sheaths are intended for use in patients requiring the percutaneous dilation of tissue to facilitate removal of cardiac leads. Rarely a patient undergoing lead extraction may require urgent surgical treatment for a complication; therefore, patients should not undergo lead extraction in centers where emergency surgical procedures cannot be performed. Leads not intended for extraction may be damaged during the procedure and may require replacement. Potential minor adverse events associated with lead extraction procedures that may or may not require medical or surgical treatment include: a tear or damage to the blood vessels, the heart or its structures; bleeding at the surgical site; or collapsed lung. Rare but serious adverse events that require emergency medical or surgical procedures may include: a tear or damage to the blood vessels, the heart, lungs or their structures; blood clot or obstruction of the blood vessels or lungs by debris or lead fragments. Other serious complications may include irregular heartbeat, weakened heart muscle, infection, respiratory failure, or complications associated with anesthesia, stroke, or death. This information is not intended to replace a discussion with your healthcare provider on the benefits and risks of this procedure to you.
Bridge Plus Occlusion Balloon important safety information The Bridge Plus Occlusion Balloon is indicated for temporary vessel occlusion of the superior vena cava and inferior vena cava in applications including perioperative occlusion and emergency control of hemorrhage. Use of the Bridge Plus Occlusion Balloon in procedures other than those indicated is not recommended. The adverse events associated with an occlusion balloon procedure include, but are not limited to allergic reactions, death, embolization, hematoma, hemorrhage, sepsis/infection, short-term hemodynamic deterioration, thromboembolic episodes, vascular thrombosis, vessel dissection, vessel perforation, vessel spasm. Prior to initiating the procedure, a Bridge Plus Occlusion Balloon Catheter compatible guidewire should be placed through a venous access site and across the length of the superior or inferior vena cava. Attempting to place the guidewire after a tear has occurred may: Result in an inability to traverse the superior or inferior vena cava with the guidewire, Result in the guidewire exiting the vasculature at the tear site, Result in an inability to place the Bridge Plus Occlusion Balloon catheter or delay or prevent the ability to achieve occlusion
This information is not intended to replace a discussion with your healthcare provider on the benefits and risks of this procedure to you. Always read the label and follow the directions for use. Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device. Products subject to country availability. Please contact your local sales representative. © Koninklijke Philips N.V. All rights reserved. Trademarks are the property of Koninklijke Philips N.V. or their respective owners. Philips reserves the right to change product specifications without prior notification.